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A series of quinoline-based agents with CNS activity have been analyzed for their three-dimensional similarity with respect to a set
of standard atypical antipsychotics. The method aligns the molecules based on their molecular ﬁelds represented as local extrema
ofelectrostatic,vanderWaals,andhydrophobicpotentialsofthemoleculetermed“ﬁeldpoints.”Thecompoundsintheserieswere
foundtodemonstraterelativelylesser3Dsimilaritytothedibenzodiazepinederivativeclozapine.Similarityvalueswerehigherwith
respect to extended chain compounds ketanserin, ziprasidone, and risperidone. The results obtained were found to agree with the
physicochemical similarity of the compounds reported earlier.
1.Introduction
Molecular similarity is one of the most widely used concepts
in the computer-aided approaches to molecular design.
According to the “molecular similarity principle,” com-
pounds with similar chemical structures are more likely
to possess similar physicochemical and biological activities
[1–6]. Despite recent examples that one cannot conclude
property similarity from structural similarity in every case
[7], this is still the underlying assumption of current drug
design eﬀorts which includes building QSAR models and
using them for making predictions for new compounds.
Some studies also indicate that structural similarity does not
always imply similarity in descriptors [8].
Theconceptofchemicalsimilaritydoesnothaveaformal
deﬁnition, and it may vary depending upon the application
for which similarity needs to be determined. Quantiﬁcation
of chemical similarity is based on numerical representation
of a chemical structure, and similarity comparisons are done
based on 2D or 3D approaches. 2D approaches involve the
calculation of ﬁngerprint-based [9] or descriptor-based sim-
ilarity [2]. The former involves a simple count of shared
features (common fragment substructures) as a measure of
quantifyingthedegreeofstructuralresemblance.Inthelatter
case, similarity can be based on descriptors such as contin-
uous whole molecule properties, for example, logP,m o l a r
refractivity, and topological indexes. Various similarity met-
rics exist that return a score indicating the level of sim-
ilarity between molecules under comparison. Frequently
used metrics are simple distance measures such as Hamming
and Euclidean distance and association coeﬃcients such as
Tanimoto, Dice, and Cosine coeﬃcients [10]. Tanimoto co-
eﬃcient has been the measure of choice for fragment-
based chemical similarity work, whereas euclidean distance
measurement is the most popular measure for continuous
data (descriptors).
3D methods can be alignment-independent methods
based on descriptors such as geometric atom pairs and their
distances, valence and torsion angles, and atom triplets and
alignment methods, which consider the conformational ﬂex-
ibility of the molecules. Field-based alignment methods [11]
are based on quantum mechanical calculations, and the sim-
ilarity score is related to the electron density of the molecules
which involves calculation of steric ﬁelds (van der Waals
surface) and electrostatic ﬁelds (derived from precalculated
point charges). Examples include methods like MIMIC [12]
using ﬁxed conformations in matching process. Flexible-
ﬁeld-based alignment (FLASHFLOOD) [13]i sp r e f e r r e d
over conformationally rigid matching [14, 15]. Comparable
activities of diverse molecules at the same molecular targets
can be explained by considering the molecules’ ﬁelds rather
than their atomic structure because the ﬁeld pattern is a far2 ISRN Pharmaceutics
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Figure 1: Alignment of compound 14 (thin sticks) with risperidone (a) and ketanserin (b). Risperidone and ketanserin are shown as capped
sticks(pink).Tetrahedraanddodecahedradepictﬁeldpointsfor14andreferencecompounds,respectively.Blue,maroon,yellow,andbrown







Compound no. X Y Ar Atypical antipsychotic
proﬁle
7 HC =O 6-quinolyl −∗
8 HC H 2 6-quinolyl −
9 HC =O 8-quinolyl −∗
10 HC H 2 8-quinolyl +
11 Cl C=O 6-quinolyl −∗
12 Cl CH2 6-quinolyl −
13 Cl C=O 8-quinolyl −∗
14 Cl CH2 8-quinolyl +
∗Show blockade only in apomorphine-induced stereotypy assay indicative
of potential to cause extrapyramidal symptoms.
superiordescriptionofmolecule’sbindingpropertiesthanits
atomic structure. Compounds which are structurally diverse
but show comparable activity have similar ﬁelds and, hence,
similar binding properties so that these can bind to the same
target site and elicit the same biological eﬀect.
We had recently reported a novel series of quinoline
derivatives evaluated for their atypical antipsychotic poten-
tial [16] and further assessed for their 2D similarity (physic-
ochemical similarity) with respect to the standard atypical
antipsychotic drugs. In the present research paper, we report
the3Dsimilarity(basedonﬁeldsimilarity,volumesimilarity,
and shape similarity) of this series of compounds to the
standard drugs clozapine, risperidone, ziprasidone, and ke-
tanserin based upon ﬁeld-based alignment methods.
2. Method
Field based similarity of the compound set was assessed
with respect to the standard drugs taken as reference, that
is, clozapine, ketanserin, ziprasidone and risperidone using
FieldAlign2.1.1 (Cresset BioMolecular Discovery Ltd., UK).
The three dimensional models of the reference drugs were
generated using ChemBio3D Ultra 12.0 and energy mini-
mization was performed with MM2 force ﬁeld to minimum
RMSgradientof0.100.Thesereferencedrugsinadeﬁned3D
conformation were then imported in sdf (MDL mol) format
to FieldAlign2.1.1. Molecules to be aligned were imported in
2D from ChemBioDraw Ultra 12.0 as sdf (MDL mol) ﬁles.
The maximum number of conformations generated for any
molecule was limited to 200 in order to have a balance of the
quality of alignments and calculation time. Number of high
temperaturedynamicsforﬂexibleringswassetat5.Gradient
cut-oﬀ for conformer minimization was 0.5. Coarseness of
the sampling of conformational space was controlled by
ﬁltering duplicate conformers at rms 0.5. Standard scoring
function was used based on 50% shape similarity and 50%
dice volume similarity to derive overall similarity between
two conformations. Further, a 3D reference template was
generated taking three reference drug molecules at a time
(loaded as single 2D structures ) using FieldTemplator2.1.1
(Cresset BioMolecular Discovery Ltd., UK) that searches for
common ﬁeld patterns across the explored conformational
space of a set of ligands looking for commonality. The best
template was selected based on their ﬁeld similarity, shape
similarity and overall similarity scores.
3. Results and Discussion
Table 1 shows the chemical structures and pharmacological
activity proﬁle of the quinoline-based compound set (7–14)
taken for the 3D alignment studies. The overall alignment
(similarity) scores along with the corresponding ﬁeld simi-
larity, volume similarity, and shape similarity scores of the
test molecules with respect to a selection of standard drugs
are shown in Tables 2, 3,a n d4. The alignment scores serve
as a measure of how similar the molecular ﬁelds of the two
molecules are in the given alignment.
Figures 1–3 show the graphic display of the best align-
ment (highest alignment score) of the compound 14 with
standard drugs along with the various ﬁeld points. Com-
pound 14 is the lead compound which had demonstratedISRN Pharmaceutics 3
Table 2: Similarity of test compounds with respect to risperidone and ketanserin.
Compd. no. Similarity Field similarity Field score Vol. Similarity Volume score Shape similarity Shape score
Ris. Ket. Ris. Ket. Ris. Ket. Ris. Ket. Ris. Ket. Ris. Ket. Ris. Ket.
7 0.620 0.672 0.483 0.539 −48.519 −52.436 0.806 0.787 204.854 193.544 0.756 0.804 192.146 197.828
8 0.619 0.648 0.541 0.480 −50.853 −46.808 0.709 0.784 201.876 191.679 0.697 0.815 175.958 199.110
9 0.659 0.686 0.552 0.576 −55.523 −57.483 0.783 0.802 198.906 197.155 0.766 0.795 193.085 193.834
10 0.610 0.683 0.525 0.565 −49.877 −55.710 0.748 0.772 189.082 188.609 0.696 0.801 175.690 195.756
11 0.661 0.689 0.542 0.594 −53.226 −59.520 0.740 0.799 194.220 203.325 0.781 0.783 205.048 199.232
12 0.626 0.659 0.512 0.501 −48.374 −49.907 0.770 0.803 200.828 202.951 0.740 0.818 193.227 206.720
13 0.676 0.721 0.581 0.635 −56.250 −64.061 0.824 0.820 216.246 208.667 0.772 0.808 202.659 205.442
14 0.658 0.716 0.549 0.610 −53.264 −58.534 0.745 0.802 194.555 202.734 0.768 0.823 200.627 208.108
Average 0.641 0.684 0.536 0.563 −51.986 −55.557 0.766 0.796 200.070 198.583 0.747 0.806 192.305 200.754
Table 3: Similarity of test compounds with respect to ziprasidone and clozapine.
Compd. no. Similarity Field similarity Field score Vol. similarity Volume score Shape similarity Shape score
Zip. Clz. Zip. Clz. Zip. Clz. Zip. Clz. Zip. Clz. Zip. Clz. Zip. Clz.
7 0.696 0.566 0.639 0.540 −66.121 −50.871 0.798 0.620 201.876 141.337 0.752 0.592 190.325 134.964
8 0.651 0.567 0.564 0.482 −58.038 −41.151 0.741 0.649 186.210 147.078 0.738 0.652 185.787 147.697
9 0.652 0.558 0.557 0.521 −58.139 −47.685 0.772 0.589 195.325 134.285 0.747 0.595 187.604 134.470
10 0.632 0.579 0.575 0.484 −59.279 −43.358 0.708 0.586 178.021 132.880 0.689 0.674 173.209 152.661
11 0.703 0.583 0.603 0.553 −59.824 −49.015 0.730 0.624 190.885 147.619 0.802 0.622 209.751 147.293
12 0.603 0.590 0.457 0.556 −45.789 −48.918 0.778 0.569 202.276 133.575 0.749 0.625 194.708 146.938
13 0.675 0.571 0.599 0.556 −62.140 −52.714 0.786 0.615 205.549 145.517 0.711 0.585 185.959 138.252
14 0.675 0.573 0.606 0.539 −63.004 −49.314 0.730 0.654 189.892 153.728 0.744 0.606 193.411 142.511
Average 0.661 0.573 0.575 0.529 −59.042 −47.878 0.755 0.613 193.754 144.002 0.742 0.619 190.094 143.098
a potential atypical antipsychotic proﬁle in our earlier stud-
ies. The best alignment obtained with risperidone shows the
ﬁeld superposition of quinoline and piperazine nitrogens
in 14 with corresponding nitrogens in the drug. The
overlap of negative ﬁeld points corresponding to the ether
oxygen in 14 and carbonyl oxygen in the drug is also seen
as a major contributor to ﬁeld similarity. The quinoline
nitrogendoesnot,however,assumecorrespondencewithany
of the two heterocyclic nitrogens in risperidone. However,
good intersection of quinoline and quinazoline nitrogens
is seen in addition to the superposition of negative ﬁeld
points of ether moiety and carbonyl group, piperazine and
piperidine nitrogens, and the corresponding halogen atoms
in 14 and ketanserin, respectively, which accounts for higher
similarity of 14 to ketanserin than to risperidone.
The best alignment of 14 with ziprasidone shows
the overlay of ﬁeld points corresponding to ether oxy-
gen in 14 with benzothiazole nitrogen in the drug. Fur-
ther, ﬁeld superposition of chlorine in 14 with carbonyl
oxygen of indolinone moiety in the drug contributes
towards the overall similarity between the two. In com-
parison to these drugs, there is less superposition of the
ﬁeld points of 14 with clozapine accounting for lower
similarity scores in this case. Further, the alignment of
14 with the three compound template generated from
risperidone, ketanserin and ziprasidone does not improve
the similarity scores as evident from the graphic display
in Figure 3.
The overall similarity scores of the compounds were
found to increase with chlorination with respect to risperi-
done, ziprasidone and ketanserin. However, compounds 10
and 14 showed nearly same similarity values with respect to
clozapine.
The 8-quinoline based compounds were found to have
higher similarity score with respect to risperidone and
ketanserin than the corresponding 6-quinoline derivatives.
However, with respect to ziprasidone, 6-quinoline com-
pounds have a higher similarity (except 14 versus 12). Fur-
ther, a pattern of increase in similarity scores with respect to
the selected standard drugs was noted which was diﬀerent
for the 8- and 6-quinoline series. The similarity for the
former was in the order clozapine<risperidone<ziprasidone
<ketanserin. Order for the 6-quinoline series was clozapine<
risperidone<ketanserin<ziprasidone.
The ﬁeld similarity with respect to ziprasidone increased
with chlorination for 8-quinoline derivatives and decreased
for 6-quinoline derivatives. With respect to the other drug
molecules, chlorination in general, increased the ﬁeld simi-
larityofthecompounds.Acomparisonof6-and8-quinoline
derivatives in terms of their ﬁeld similarity scores showed
that 8-quinoline derivatives have a greater ﬁeld similarity to
ziprasidone than their corresponding 6-quinoline analogs.
However, with respect to clozapine, scores were not signiﬁ-
cantly diﬀerent.
Shape similarity with respect to risperidone and ziprasi-
done (except 8-quinolyl benzoyl derivative 7) showed an4 ISRN Pharmaceutics
(c) (d)
Figure 2: Alignment of compound 14 (thin sticks) with ziprasidone (c) and clozapine (d). Ziprasidone and clozapine are shown as capped
sticks (pink). Field point depiction is the same as in Figure 1.
Table 4: Similarity of test compounds with respect to chlorpromazine and template.
Compd. no. Similarity Field similarity Field score Vol. similarity Volume score Shape similarity Shape score
CPZ Temp CPZ Temp CPZ Temp CPZ Temp CPZ Temp CPZ Temp CPZ Temp
7 0.613 0.603 0.535 0.466 −48.258 −47.987 0.628 0.620 141.826 141.337 0.690 0.740 164.092 185.972
8 0.565 0.579 0.487 0.469 −41.443 −46.261 0.641 0.649 147.210 147.078 0.643 0.689 151.980 172.277
9 0.557 0.575 0.532 0.451 −49.327 −45.631 0.572 0.589 135.325 134.285 0.583 0.699 137.385 174.194
10 0.561 0.576 0.517 0.425 −46.640 −41.811 0.588 0.586 138.021 132.880 0.606 0.728 143.205 181.874
11 0.543 0.596 0.493 0.456 −46.066 −44.811 0.630 0.624 141.855 147.619 0.592 0.736 145.862 191.305
12 0.581 0.582 0.500 0.436 −43.990 −44.166 0.578 0.569 136.276 133.575 0.662 0.728 162.107 188.021
13 0.599 0.635 0.520 0.543 −48.090 −54.255 0.616 0.615 145.549 145.517 0.679 0.726 167.193 188.809
14 0.591 0.618 0.538 0.489 −51.045 −49.919 0.630 0.654 142.092 153.728 0.644 0.748 157.594 193.364
Average 0.576 0.596 0.515 0.467 −46.857 −46.855 0.610 0.613 141.019 142.002 0.637 0.724 153.677 184.477
Figure 3: Alignment of compound 14 (thin sticks) with three
compound templates generated from risperidone, ketanserin, and
ziprasidone shown as capped sticks (pink). Field point depiction is
the same as in Figure 1.
increase with chlorination. No particular pattern was seen
on chlorination with respect to ketanserin. A comparison
between 6- and 8-quinolyl derivatives showed that, for non-
chlorinated compounds, the latter showed higher shape sim-
ilarity to ketanserin and clozapine whereas, for chlorinated
analogs, 6-quinoline derivatives showed higher scores.
Further, as expected, the volume similarity values were
not signiﬁcantly changed on chlorination or in the compari-
son of the 6- and 8-quinolyl derivatives.
Theaveragesimilarityscoresforthecompoundswerethe
highest with respect to ketanserin followed by ziprasidone
andrisperidone.Interestingly,thephysicochemicalsimilarity
for the compounds reported earlier was the lowest with
respect to ketanserin for the same drug group (90.64%,
85.5%, and 76.7% with respect to ziprasidone, risperidone
and ketanserin, resp.). In line with the results from our
previous computational studies, wherein the physicochem-
ical similarity was the lowest with respect to the more
compact dibenzodiazepine derivative clozapine (56.85%),
the3Dsimilarity valueswerealsofoundto bethelowest with
respect to clozapine as well as the conventional neuroleptic
chlorpromazine.
Ananalysisofthebreakupoftheoverallalignmentscores
shows that the contribution of the shape and volume simi-
larity was signiﬁcantly greater than the corresponding ﬁeld
similarity values in all the cases. As can be seen from the
tables, the shape similarity and volume similarity is more
than 0.7 for all the drug examples (except clozapine) whereas
their ﬁeld similarity scores range from 0.54 to 0.58.
4. Conclusions
In the present work, a set of quinolyloxypropyl piperazine
derivatives have been analyzed for their three-dimensional
similarity to a selection of atypical antipsychotic drugs,
and these demonstrate higher similarity with respect to theISRN Pharmaceutics 5
extended chain structures such as risperidone, ziprasidone,
and ketanserin and lesser similarity to the prototypic agent
clozapine. Further, speciﬁc patterns were observed for the
changeinsimilarityscoreswithchangeinchemicalstructure.
An introspection of the ﬁeld alignments obtained for the
molecules (especially, the lead compound from our studies
14) with respect to standard drugs suggests a good corre-
spondence of quinoline nitrogen, piperazine system, ether
oxygen, and chlorine atom with the corresponding group-
ings in the standard drug molecules. This highlights the
importance of these structural features as a part of the chro-
mophoric system involved in the pharmacological activity
of this class of compounds. Further development of this
compound series can be carried out by appropriate modi-
ﬁcations whilst retaining these salient features. Hence, the
information generated from the molecular ﬁeld analysis of
this compound series can be used as a valuable tool for
designing novel analogues by interpretation of their phar-
macological activity in terms of their ﬁeld pattern.
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